The rescinded order directed Medicare and Medicaid to test ways to lower drug costs for enrollees. Those tests hadn’t started, so current drug prices are unaffected.

The Trump administration’s first drug pricing action — rescinding a Biden executive order encouraging Medicare to help lower prescription costs — is befuddling drug pricing experts.

Trump has so far not targeted any of Biden's signature healthcare policies, including Medicare drug pricing negotiation powers, the $35 monthly cap on insulin copays, and the $2,000 annual cap on out-of-pocket spending on prescription drug costs.